Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Takeshi Terashima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1052-0101; OpenAlex author ID A5058321251, A5110439328. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 6 papers · 2026: 1 paper

Papers 18

  1. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  2. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  3. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  4. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  5. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  6. Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44276-024-00116-z↗
  7. Metachronous Pancreatic Cancer with Pancreaticobiliary Maljunction Diagnosed Five Years after Cholecystectomy for Gallbladder Cancer, in Which Follow-up Imagin… Co-author DOI 10.2169/internalmedicine.4581-24↗
  8. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  9. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  10. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  11. Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s40780-021-00236-5↗
  12. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  13. Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. Co-author PMID 34249452↗
  14. Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. Co-author DOI 10.1080/09553002.2019.1558297↗
  15. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells. Co-author DOI 10.1111/cas.13971↗
  16. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Co-author DOI 10.1093/jjco/hyy132↗
  17. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  18. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-014-1529-8↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chigusa Morizane · 9 shared papers, 2017–2026 · strength 1.41
  2. Makoto Ueno · 9 shared papers, 2017–2025 · strength 1.37
  3. Junji Furuse · 9 shared papers, 2017–2025 · strength 1.30
  4. Masafumi Ikeda · 8 shared papers, 2021–2025 · strength 1.26
  5. Masato Ozaka · 5 shared papers, 2023–2026 · strength 0.93
  6. Naohiro Okano · 5 shared papers, 2023–2025 · strength 0.85
  7. Satoshi Kobayashi · 5 shared papers, 2023–2025 · strength 0.80
  8. Hiroshi Imaoka · 5 shared papers, 2023–2025 · strength 0.80
  9. Akihiro Ohba · 4 shared papers, 2023–2025 · strength 0.67
  10. Nobumasa Mizuno · 5 shared papers, 2017–2026 · strength 0.64
  11. Kunihiro Tsuji · 4 shared papers, 2022–2025 · strength 0.64
  12. Kumiko Umemoto · 4 shared papers, 2021–2025 · strength 0.62
  13. Kohei Nakachi · 4 shared papers, 2023–2025 · strength 0.62
  14. Taro Yamashita · 4 shared papers, 2019–2025 · strength 0.57
  15. Hiroaki Nagano · 3 shared papers, 2025–2026 · strength 0.56
  16. Hiroshi Ohyama · 3 shared papers, 2025–2026 · strength 0.56
  17. Yasuyuki Kawamoto · 3 shared papers, 2025 · strength 0.51
  18. Akihiro Seki · 3 shared papers, 2019–2025 · strength 0.47
  19. Kenji Ikezawa · 2 shared papers, 2025–2026 · strength 0.45
  20. Masaki Miyazawa · 2 shared papers, 2025 · strength 0.39
  21. Reiko Ashida · 3 shared papers, 2017–2025 · strength 0.37
  22. Yoshito Komatsu · 2 shared papers, 2023–2026 · strength 0.36
  23. Takuji Okusaka · 2 shared papers, 2023–2025 · strength 0.34
  24. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  25. Yohei Kitano · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.